Gadolinium contrast and mpMRI scans

In his latest epistle to the medical community on the MedPage Today web site, prostate cancer patient Howard Wolinsky writes about the need (or lack of need) for the use of gadolinium-containing contrast agents associated with the conduct of multiparametric MRI (mpMRI) scans. … READ MORE …

If you are or ever were a fighter pilot …

Apparently the US Air Force (USAF) has become concerned that being a fighter pilot may increase risk for a diagnosis of prostate cancer. For those who are interested, here’s a link to the relevant article on the McClatchy news service. … READ MORE …

The continuing importance of the digital rectal exam

Many men dislike digital rectal examinations (DREs) — for all sorts of reasons. However, a new study has again pointed out the value of the DRE in helping to establish clinical risk and the potential aggressiveness of a specific prostate cancer diagnosis in each individual patient. … READ MORE …

Geographic risk for advanced and metastatic prostate cancer

New research data on the epidemiology of advanced prostate cancer here in the US has confirmed something that has long been understood (albeit not previously as well documented). … READ MORE …

ADT is associated with risk for Alzheimer’s and dementia in largest study to date

According to the newest and largest known analysis of data currently available, there is a small but statistically significant association between treatment with androgen deprivation therapy (ADT) and increase in risk for Alzheimer’s disease and/or dementia over time. … READ MORE …

New urine test shows promising results in detecting, classifying risk for prostate cancer

A newly published article in BJU International has described a way to test post-DRE urine samples for the presence of specific types of ribonucleic acid (RNA) and use these data to detect and classify risk levels for more and less aggressive forms of prostate cancer. … READ MORE …

Mutations to FOXA1 may be key to some aggressive forms of prostate cancer

A newly published study by researchers at the University of Michigan has clarified the potential roles of a transcription factor called “forkhead box A1” (FOXA1) in hormone-driven forms of prostate cancer and some other forms of hormone-driven cancer (e.g., breast cancer). … READ MORE …